Purpose

This is a Phase 1/2/3 study in healthy children <12 years of age. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

Condition

Eligibility

Eligible Ages
Between 6 Months and 11 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Male or female participants ≥6 months to <12 years of age, at the time of randomization, at Visit 1. - Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. - Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study. - Participants are expected to be available for the duration of the study and whose - parent(s)/legal guardian can be contacted by telephone during study participation. - Negative urine pregnancy test for female participants who are biologically capable of having children. - Female participant of childbearing potential or male participant able to father children who is willing to use a highly effective method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention if at risk of pregnancy with her/his partner; or female participant not of childbearing potential or male participant not able to father children. - The participant's parent(s)/legal guardian is capable of giving signed informed consent.

Exclusion Criteria

  • Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a - SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19. - Phase 1 only: Known infection with HIV, HCV, or HBV. - Receipt of medications intended to prevent COVID-19. - Previous or current diagnosis of MIS-C. - Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. - History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). - Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. - Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. - Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. - Female who is pregnant or breastfeeding. - Previous vaccination with any coronavirus vaccine. - Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. - Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study. - Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. - Previous participation in other studies involving study intervention containing LNPs. - Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Low-Dose, ≥5 to <12 Years old
Low-Dose (10mcg), 2 doses 21 days apart
  • Biological: Biological/Vaccine: BNT162b2 10mcg
    BNT162b2 Low-Dose (10mcg) level
Experimental
Mid-Dose, ≥5 to <12 Years old
Mid-Dose, (20mcg), 2 doses 21 days apart
  • Biological: BNT162b2 20mcg
    BNT162b2 Mid-Dose (20mcg) level
Experimental
High-Dose, ≥5 to <12 Years old
High-Dose (30mcg), 2 doses 21 days apart
  • Biological: BNT162b2 30mcg
    BNT162b2 High-Dose (30mcg) level
Experimental
Low-Dose, ≥2 to < 5 Years old
Low Dose (10mcg), 2 doses 21 days apart
  • Biological: Biological/Vaccine: BNT162b2 10mcg
    BNT162b2 Low-Dose (10mcg) level
Experimental
Mid-Dose, ≥2 to <5 Years old
Mid-Dose, (20mcg), 2 doses 21 days apart
  • Biological: BNT162b2 20mcg
    BNT162b2 Mid-Dose (20mcg) level
Experimental
High-Dose, ≥2 to <5 Years old
High-Dose, (30mcg), 2 doses 21 days apart
  • Biological: BNT162b2 30mcg
    BNT162b2 High-Dose (30mcg) level
Experimental
Low-Dose, ≥6 Months to <2 years old
Low-Dose, (10mcg), doses 21 days apart
  • Biological: Biological/Vaccine: BNT162b2 10mcg
    BNT162b2 Low-Dose (10mcg) level
Experimental
Mid-Dose, ≥6 Months to <2 years old
Mid-Dose, (20mcg), doses 21 days apart
  • Biological: BNT162b2 20mcg
    BNT162b2 Mid-Dose (20mcg) level
Experimental
High-Dose, ≥6 Months to <2 years old
High-Dose, (30mcg), 2 doses 21 days apart
  • Biological: BNT162b2 30mcg
    BNT162b2 High-Dose (30mcg) level

Recruiting Locations

University of Kansas Medical Center - CTSU
Fairway, Kansas 66205

More Details

Status
Recruiting
Sponsor
BioNTech SE

Study Contact

Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

Detailed Description

Phase 1 is the open-label dose-finding portion of the study to evaluate safety, tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days) schedule in up to 3 age groups (participants ≥5 to <12 years, ≥2 to <5 years, and ≥6 months to <2 years of age). Dose finding is being initiated in this study in participants ≥5 to <12 years of age based on the acceptable blinded safety assessment of the 30-μg dose in 12- to 15-year-olds in the C4591001 study. The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3 different dose levels in each age group. Phase 2/3 will evaluate the safety, tolerability, and immunogenicity in each age group at the selected dose level from Phase 1. Efficacy will be evaluated across all age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases across those age groups. All participants will have blood drawn at baseline prior to Dose 1 and 6 months after Dose 2. Immunobridging to participants 16 to 25 years of age in the C4591001 study will be based on immunogenicity data collected at baseline and 1 month after Dose 2. The persistence of the immune response will be based on immunogenicity data collected in participants at baseline and at 1, 6, 12 (original BNT162b2 group only), and 24 months after Dose 2 (original BNT162b2 group only). In addition, efficacy against confirmed COVID-19 and against asymptomatic infection will also be assessed. At the 6-month follow-up visit, all participants will be unblinded. Participants who originally received placebo will be offered the opportunity to receive BNT162b2 as part of the study. Approximately 450 participants (300 in the active vaccine group and 150 in the placebo group) randomized in each age group in this phase will contribute to the immunobridging analysis at 1 month after Dose 2 and will contribute to the overall analysis of the persistence of immune response at 6 months after Dose 2. These participants will be enrolled from both US and EU sites to ensure this subset is representative of the whole study. For the persistence time points of 12 and 24 months after Dose 2, approximately 70 participants from each age group in the original BNT162b2 vaccine group will have an immunogenicity blood draw in order to contribute to the analysis. All approximately 4500 participants will contribute to the VE analysis for conditional VE and asymptomatic infection. Efficacy will be evaluated across all age groups in which immunobridging is successful, depending on accrual of a sufficient number of cases across those age groups.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.